128140-72-7Relevant academic research and scientific papers
Copper-Catalyzed Decarboxylative Difluoromethylation
Zeng, Xiaojun,Yan, Wenhao,Zacate, Samson B.,Chao, Tzu-Hsuan,Sun, Xiaodong,Cao, Zhi,Bradford, Kate G. E.,Paeth, Matthew,Tyndall, Sam B.,Yang, Kundi,Kuo, Tung-Chun,Cheng, Mu-Jeng,Liu, Wei
, p. 11398 - 11403 (2019/08/20)
We report herein a highly efficient Cu-catalyzed protocol for the conversion of aliphatic carboxylic acids to the corresponding difluoromethylated analogues. This robust, operationally simple and scalable protocol tolerates a variety of functional groups and can convert a diverse array of acid-containing complex molecules to the alkyl-CF2H products. Mechanistic studies support the involvement of alkyl radicals.
ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES
-
Page/Page column 110, (2014/01/09)
The invention provides compounds of formula la, lb and Ic: [Formula Ia, Ib, and Ic] and salts thereof, wherein variables are as described in the specification, as well as compositions comprising a compound of formula Ia-Ic, methods of making such compounds, and methods of using such compounds, e.g., as inhibitors of bacterial RNA polymerase and as antibacterial agents.
SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
-
Page/Page column 53, (2008/06/13)
A pharmaceutical composition comprising a compound having Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein, R1 is, for example, a C6-C10 aryl group which may be substituted with one group or more than one group selected from substituent group α; R2 is, for example, a C6-C10 aryl group which may be substituted with one group or more than one group selected from substituent group α; and X is, for example, a hydroxyl group or a C1-C6 alkoxy group].
SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
-
Page/Page column 71, (2008/06/13)
It is an object of the present invention to provide a substituted propanamide derivative or a pharmacologically acceptable salt thereof that is useful as a prophylactic or therapeutic agent for a bone metabolic disease. The present invention relates to a pharmaceutical composition comprising a compound having General Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein, R1 represents a C6-C10 aryl group that may be substituted by a group selected from Substituent Group α, for example; R2 represents a C6-C10aryl group that may be substituted by a group selected from Substituent Group α, for example; and X represents a hydroxyl group or a C1-C6 alkoxy group, for example].
